Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 11Leukemia, Myeloid, Acute 10Lung Neoplasms 9Myelodysplastic Syndromes 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Carcinoma, Non-Small-Cell Lung 5Leukemia, Biphenotypic, Acute 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Pancreatic Neoplasms 3Osteosarcoma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Thyroid Cancer, Papillary 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Myeloproliferative Disorders 2Mycosis Fungoides 2Melanoma 2

Interventions

Rituximab 41Cyclophosphamide 37Magnetic Resonance Spectroscopy 22Specimen Handling 20Prednisone 19Doxorubicin 19polatuzumab vedotin 18Lenalidomide 17Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13Vincristine 12zanubrutinib 11Immunotherapy, Adoptive 11Etoposide 10glofitamab 8obinutuzumab 7axicabtagene ciloleucel 7Prednisolone 7ibrutinib 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6CT-P10 6Bendamustine Hydrochloride 6orelabrutinib 5loncastuximab tesirine 5fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × X-Rays × Clear all
NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT07098364 2026-01-14

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
33 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

University of Washington

Phase 1/2 Recruiting
35 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡